A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1501-1505

  Kudelka, Andrzej P ^a   Levy, Tally ^b   Verschraegen, Claire F ^a   Edwards, Creighton L ^a   Piamsomboon, Surintip ^c   Termrungruanglert, Wichai ^d   Freedman, Ralph S ^a   Kaplan, Alan L ^b   Kieback, Dirk G ^b   Meyers, Christina A ^a   Jaeckle, Kurt A ^a   Loyer, Evelyne ^a   Steger, Melissa ^a   Mante, Rosario ^a   Mavligit, Giora ^a   Killian, Anthony ^e   Tang, Rosa A ^a   Gutterman, Jordon U ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^e TAP Holdings Limited   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NAUSEA; NEOVASCULARIZATION, PATHOLOGIC; NERVOUS SYSTEM DISEASES; SALVAGE THERAPY; SESQUITERPENES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 0030816274     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 18: 1182-1186, 1971.
2. Folkman, J. Tumor angiogenesis. Adv. Cancer. Res., 43: 175-203, 1985.
3. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (Lond.), 348: 555-557, 1990.
4. Killough, J. H., Magill, G. B., and Smith, R. C. The treatment of amebiasis with fumagillin. Science (Washington, DC), 15: 71-72, 1952.
5. Sipos, E. P., Tamargo, R. J., Weingart, J. D., and Brem, H. Inhibition of tumor angiogenesis. Ann. NY Acad. Sci., 732: 263-272, 1994.
6. Brem, H., Ingber, D., Blood, C. H., Bradley, D., Urioste S., and Folkman, J. Suppression of tumor metastasis by angiogenesis inhibition. Surg. Forum. 42: 439-441, 1991.
7. Kusaka, M., Sudo, K., Fujita, T., Marui, S., Itoh, F., Ingber, D., and Folkman, J. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun., 174: 1070-1076, 1991.
8. Tanaka, T., Konno, H., Matsuda, I., Nakamura, S., and Baba, S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res., 55: 836-839, 1995.
9. Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K., and Fujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res., 53: 5233-5236, 1993.
10. Yanase, T., Tamura, M., Fujita, K., Kodama, S., and Tanaka, K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res., 53: 2566-2570, 1993.
11. Takamiya, Y., Friedlander, R. M., Brem, H., Malick, A., and Martuza, R. L. Inhibition of angiogenesis and growth of human nervesheath tumors by AGM-1470. J. Neurosurg., 78: 470-476, 1993.
12. Parkin, D.M., Muir, C. S. Cancer incidence in five continents: comparability and quality of data. IARC Scientific Publications, Lyon, France. 120: 45-173, 1992.
13. Disaia, P. J., and Creasman, W. T. Invasive cervical cancer. In: P. J. Disaia and W. T. Creasman (eds.), Clinical Gynecologic Oncology, pp. 58-125. St. Louis: Mosby Year Book, 1993.
14. Alberts, D. S., Garcia, D., and Mason-Liddil, N. Cisplatin in advanced cancer of the cervix: an update. Semin. Oncol., 18: 11-24, 1991.
15. Omura, G. A. Current status of chemotherapy for cancer of the cervix. Oncology (Base 1), 6: 27-32, 1992.
16. Lippman, S. M., Kavanagh, J. J., Paredes-Espinoza, M., Delgadillo-Madrueno, F., Paredes-Casillas, P., Hong, W. K. Holender, E., and Krakoff, I. H. 13-cis retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J. Natl. Cancer Inst., 84: 241-245, 1991.
17. Ahn, W. S., Lippman, S. M., Kavanagh, J. J., Silva, E. G., Hong, W. K., Krakoff, I. H., and Hittelman, W. N. Biological basis of response of cervical squamous cell carcinoma to α interferon and 13-cis retinoic acid. Proc. Am. Assoc. Cancer Res., 34: 75, 1993.
18. Ezekowitz, H. A., Mulliken, J. B., and Folkman, J. Interferon α-2a therapy for life-threatening hemangioma of infancy. N. Engl. J. Med., 326: 1456-1463, 1992.
19. WHO. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publ. No. 48. Geneva: WHO, 1979.
20. Yamaoka, M., Yamamoto, T., Masaki, T., Ikeyama, S., Sudo, K., and Fujita, T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res., 53: 4262-4267, 1993.
21. Brem, H., and Folkman J. Analysis of experimental antiangiogenic therapy. J. Ped. Surg., 28: 445-451, 1993.
22. Kusaka, M., Sudo, K., Matsutani, E., Kozai, Y., Marui, S., Fujita, T., Ingber, D., and Folkman, J. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer, 69: 212-216, 1994.
23. TNP-470: information for clinical investigators. TAP Holding Inc. Deerfield, IL 60015, April 1995.
24. Konno, H., Tanaka, T., Matsuda, I., Kanai, T., Maruo, Y., Nishino, N., Nakamura, S., and Baba, S. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer. Int. J. Cancer, 61: 268-271, 1995.
25. Teicher, B. A., Holden, S. A., Ara, G., Alvarez Sotomayor, E., Huang, Z. D., Chen, Y. N., and Brem, H. Potentiation of cytotoxic cancer therapy by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer. 57: 920-925, 1994.
26. Kanai, T., Konno, H., Tanaka, T., and Baba, S. Inhibition of metastases of human stomach cancer constructed using orthotopic implantation in nude mice by angiogenesis inhibitor TNP-470. Proc. Am. Assoc. Cancer Res., 37: 56, 1996.
27. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth-factor-induced angiogenesis-suppressed tumor growth in vivo. Nature (Lond.), 362: 841-844, 1993.